Skip to content
10-Q

Quarterly Report

PDS BIOTECHNOLOGY CORPORATION PDSB

0001140361-26-021286

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 55.82M sh
Shares Diluted Q1 2026 · Mar 31, 2026 55.5M sh
Shares Diluted Q1 2026 · Mar 31, 2025 40.52M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.37M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$9.03M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $21.66M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $26.71M
Stockholders Equity Q1 2026 · Mar 31, 2026 $3.89M
Stockholders Equity Q1 2026 · Dec 31, 2025 $9.25M
Stockholders Equity Q1 2026 · Mar 31, 2025 $22.36M
Stockholders Equity Q1 2026 · Dec 31, 2024 $19M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.15M
Current Liabilities Q1 2026 · Dec 31, 2025 $9.48M
Total Liabilities Q1 2026 · Mar 31, 2026 $20.77M
Total Liabilities Q1 2026 · Dec 31, 2025 $21.24M
Current Assets Q1 2026 · Mar 31, 2026 $22.89M
Current Assets Q1 2026 · Dec 31, 2025 $28.25M
Total Assets Q1 2026 · Mar 31, 2026 $24.66M
Total Assets Q1 2026 · Dec 31, 2025 $30.49M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.13
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.21
Eps Basic Q1 2026 · Mar 31, 2026 −$0.13
Eps Basic Q1 2026 · Mar 31, 2025 −$0.21
Sga Expense Q1 2026 · Mar 31, 2026 $3.06M
Sga Expense Q1 2026 · Mar 31, 2025 $3.27M
Rd Expense Q1 2026 · Mar 31, 2026 $3.46M
Rd Expense Q1 2026 · Mar 31, 2025 $5.83M
Net Income Q1 2026 · Mar 31, 2026 −$7.35M
Net Income Q1 2026 · Mar 31, 2025 −$8.49M
Operating Income Q1 2026 · Mar 31, 2026 −$6.52M
Operating Income Q1 2026 · Mar 31, 2025 −$9.11M